查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933348

全球乙型肝炎治療市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的分析以及未來預測（2026-2034）

Hepatitis B Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 161 Pages | 商品交期: 請詢問到貨日

價格

B型肝炎治療市場成長因素

受乙型肝炎感染病例增加以及政府加強宣傳、提高診斷率和治療普及率等因素的推動，全球乙型肝炎治療市場正經歷強勁增長。根據 Fortune Business Insights 的一項研究顯示，2025 年全球乙型肝炎治療市場規模預計將達到 24.8 億美元。預計該市場將從 2026 年的 26.7 億美元成長到 2034 年的 66.6 億美元，預測期內複合年增長率 (CAGR) 為 12.09%。北美地區憑藉先進的醫療基礎設施和較高的治療普及率，在 2025 年將以 52.31% 的市場佔有率領先。

乙型肝炎的治療方法包括抗病毒藥物和免疫調節劑，用於治療急性和慢性乙型肝炎病毒 (HBV) 感染。 HBV 的傳播途徑包括性接觸、接觸受感染的血液和體液，以及分娩期間的母嬰傳播。日益加重的全球疾病負擔以及對消除病毒性肝炎這一公共衛生威脅的日益重視，是推動市場擴張的關鍵因素。

市場動態

市場驅動因素

B型肝炎盛行率的上升是推動市場成長的關鍵因素。乙型肝炎是一種嚴重的肝臟感染，如果不治療，可發展為慢性疾病、肝硬化和肝細胞癌。根據世界衛生組織 (WHO) 截至 2022 年對 187 個國家的數據，全球約有 2.54 億人感染B型肝炎，但只有一小部分慢性患者接受治療。 大量未接受治療的患者群體推動了對有效診斷方法和長期治療管理的需求，從而促進了乙型肝炎治療市場的成長。

市場限制因子

慢性B型肝炎患者抗病毒藥物抗藥性的出現是主要限制因素。長期使用核苷/核苷酸類似物會導致病毒突變，降低藥物療效並導致治療失敗。對拉米夫定和阿德福韋酯等常用藥物的抗藥性限制了其長期療效，阻礙了持續治療，並抑制了市場成長。

市場機會

現有單藥療法的限制以及抗藥性乙型肝炎病毒株的出現，為開發新型療法和聯合療法創造了充滿希望的機會。多家製藥和生技公司正在開發針對乙型肝炎病毒生命週期多個階段的在研產品。預計在預測期內，聯合療法和新一代抗病毒藥物將滿足未被滿足的醫療需求，並顯著擴展治療選擇。

市場挑戰

長期抗病毒治療的高昂費用仍然是一項重大挑戰，尤其是在中低收入國家。慢性B型肝炎需要長期治療和持續監測，對患者和醫療保健系統造成沉重的經濟負擔。每日口服藥物依從性低進一步增加了抗藥性的風險，對市場的可持續成長構成挑戰。

B型肝炎藥物市場趨勢

市場的一個顯著趨勢是，人們越來越關注針對共價閉合環狀DNA (cccDNA) 和整合的乙型肝炎病毒DNA的治癒性療法，這些DNA是導致持續性病毒感染的原因。目前的療法可以抑制病毒複製，但無法根除cccDNA，導致疾病復發。 這種情況加速了基因編輯、RNA幹擾和免疫療法的研究，預示著慢性B型肝炎的治療方向正轉向根治性治療。

市場區隔分析

依藥物類別劃分，核苷類似物將在2026年佔市場主導地位，市佔率達74.03%。這主要歸功於其廣泛的處方歷史以及抑制病毒複製的能力。核苷酸類似物曾佔第二大市場佔有率，但由於抗藥性的增加，其成長速度已放緩。幹擾素將保持相當大的市場佔有率，這得益於聯合療法研究的持續開展；而其他細分市場預計將因新型療法的開發而實現顯著增長。

依年齡組別劃分，成人將在2026年佔最大市場佔有率，達77.87%。這主要歸功於較高的感染率和擴大的成人篩檢項目。由於有效的疫苗接種計劃，兒童的市場佔有率將相對較小，但隨著適應症的擴大，其市場佔有率預計將保持適度增長。

依給藥途徑劃分，口服給藥途徑將在2026年佔市場主導地位，市佔率高達94.76%，主要得益於其便利性和病患依從性。由於生物利用度的提高和新型注射療法的出現，腸外給藥途徑預計將穩定成長。

依分銷管道劃分，零售藥局將在2026年佔市場主導地位，市場佔有率為52.53%，而線上藥局預計將以最高的複合年增長率增長，這主要得益於數位化進程的推進。

區域展望

北美地區將在2025年佔市場主導地位，市場規模將達到13.2億美元，主要得益於較高的疾病認知度和強有力的健保政策。 預計2026年，美國市場規模將達到13.6億美元。

亞太地區佔第二大市場佔有率，預計成長速度最快，這主要得益於該地區疾病高發生率和價格低廉的仿製藥的廣泛普及。預計到2026年，中國市場規模將達到5.6億美元。

歐洲繼續佔較大市場佔有率，這得益於其先進的醫療保健體系和不斷上升的乙肝病毒感染率。

由於政府主導的根除計畫的增加，拉丁美洲和中東/非洲地區預計將保持穩定成長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家乙型肝炎流行率（2025 年）
  • 主要產業趨勢：新產品發布、併購、業務合作等
  • 主要公司產品線分析
  • B型肝炎治療進展
  • 主要國家乙型肝炎疫苗接種率概述國家/地區
  • 關稅對市場的影響

第五章 全球B型肝炎治療市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依藥物類別劃分
    • 核苷類似物
    • 核苷酸類似物
    • 幹擾素
    • 其他
  • 市場分析、洞察與預測：依年齡組別劃分
    • 成人
    • 兒童
  • 市場分析、洞察與預測：依給藥途徑劃分
    • 口服
    • 腸外給藥
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美乙型肝炎治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲乙型肝炎治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 美國王國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 其他歐洲國家

第八章 亞太地區乙型肝炎治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲乙型肝炎治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區美國

第十章：中東與非洲B型肝炎治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb Company
    • GSK plc
    • Excision BioTherapeutics, Inc.
    • Arbutus Biopharma
    • Assembly Biosciences, Inc.
    • Aligos Therapeutics
    • Barinthus Biotherapeutics
Product Code: FBI113651

Growth Factors of hepatitis B therapeutics Market

The global hepatitis B therapeutics market is witnessing strong growth driven by the rising prevalence of hepatitis B infection worldwide and increasing government initiatives to improve awareness, diagnosis, and treatment adoption. According to Fortune Business Insights, the global hepatitis B therapeutics market was valued at USD 2.48 billion in 2025. The market is projected to grow from USD 2.67 billion in 2026 to USD 6.66 billion by 2034, registering a CAGR of 12.09% during the forecast period. In 2025, North America dominated the market with a share of 52.31%, supported by advanced healthcare infrastructure and high treatment adoption rates.

Hepatitis B therapeutics include antiviral drugs and immune-modulating agents used to manage acute and chronic hepatitis B virus (HBV) infections. HBV is transmitted through sexual contact, exposure to infected blood or bodily fluids, and from mother to child during birth. The growing global disease burden and increasing focus on eliminating viral hepatitis as a public health threat are key factors driving the market's expansion.

Market Dynamics

Market Drivers

The rising prevalence of hepatitis B is a major driver of market growth. Hepatitis B is a serious liver infection that can progress to chronic disease, liver cirrhosis, and hepatocellular carcinoma if left untreated. According to the World Health Organization, based on 2022 data from 187 countries, approximately 254 million people globally were living with hepatitis B infection, while only a small proportion of chronic patients were receiving treatment. This large untreated population has increased the demand for effective diagnosis and long-term therapeutic management, thereby driving the hepatitis B therapeutics market.

Market Restraints

The emergence of antiviral drug resistance in chronic hepatitis B patients is a significant restraint. Long-term use of nucleoside and nucleotide analogues can lead to viral mutations, resulting in reduced drug efficacy and treatment failure. Resistance to commonly used drugs such as lamivudine and adefovir dipivoxil has limited their long-term effectiveness, discouraging sustained therapy and restraining market growth.

Market Opportunities

The limitations of existing monotherapies and the growing burden of drug-resistant HBV strains are creating lucrative opportunities for the development of novel and combination therapies. Several pharmaceutical and biotechnology companies are advancing pipeline products targeting multiple stages of the HBV lifecycle. Combination regimens and next-generation antivirals are expected to address unmet clinical needs and significantly expand treatment options during the forecast period.

Market Challenges

High treatment costs associated with long-term antiviral therapy remain a major challenge, particularly in low- and middle-income countries. Chronic hepatitis B requires prolonged treatment and continuous monitoring, increasing financial strain on patients and healthcare systems. Poor medication adherence due to daily oral regimens further elevates the risk of resistance development, posing challenges to sustained market growth.

Hepatitis B Therapeutics Market Trends

A prominent trend in the market is the growing focus on curative therapies targeting covalently closed circular DNA (cccDNA) and integrated HBV DNA, which are responsible for viral persistence. Current therapies suppress viral replication but do not eradicate cccDNA, leading to disease recurrence. This has accelerated research into gene-editing, RNA interference, and immune-based therapies, signaling a shift toward potentially curative treatment approaches for chronic hepatitis B.

Segmentation Analysis

By drug class, nucleoside analogues dominated the market with a share of 74.03% in 2026, driven by their widespread prescription and effectiveness in suppressing viral replication. Nucleotide analogues held the second-largest share but showed slower growth due to rising resistance. Interferons maintained a considerable share owing to ongoing research into combination therapies, while the others segment is expected to grow significantly due to innovation in novel treatment modalities.

By age group, adults accounted for the largest share of 77.87% in 2026, attributed to higher transmission rates and expanded adult screening programs. The pediatric segment held a smaller share due to effective vaccination programs but is expected to grow moderately with expanding drug indications.

By route of administration, the oral segment dominated with a share of 94.76% in 2026, supported by convenience and patient compliance. Parenteral therapies are expected to grow steadily due to improved bioavailability and emerging injectable therapies.

By distribution channel, retail pharmacies led the market with a share of 52.53% in 2026, while online pharmacies are expected to grow at the highest CAGR due to increasing digital adoption.

Regional Outlook

North America dominated the market with a value of USD 1.32 billion in 2025, driven by high disease awareness and strong reimbursement policies. The U.S. market is projected to reach USD 1.36 billion by 2026.

Asia Pacific held the second-largest share and is expected to grow at the fastest rate due to high disease prevalence and availability of affordable generics, with China projected to reach USD 0.56 billion by 2026.

Europe maintained a substantial share, supported by advanced healthcare systems and rising HBV prevalence.

Latin America and the Middle East & Africa are expected to grow steadily due to increasing government-led elimination programs.

Competitive Landscape

The market is consolidated, with Gilead Sciences, Inc. and Bristol-Myers Squibb Company holding leading positions due to strong product portfolios and consistent sales. Other notable players include GSK plc, Arbutus Biopharma, Assembly Biosciences, Aligos Therapeutics, and Excision BioTherapeutics, focusing on pipeline expansion and innovative therapies.

Conclusion

The global hepatitis B therapeutics market is positioned for strong growth through the forecast period, driven by the rising global burden of hepatitis B, expanding screening programs, and continuous advancements in therapeutic innovation. With the market valued at USD 2.48 billion in 2025, projected to grow to USD 2.67 billion in 2026 and reach USD 6.66 billion by 2034, increasing adoption of novel antiviral combinations and curative treatment approaches is expected to reshape the treatment landscape. Despite challenges related to drug resistance and high treatment costs, sustained government initiatives and ongoing research and development efforts are anticipated to support long-term market expansion.

Segmentation By Drug Class

  • Nucleoside Analogues
  • Nucleotide Analogues
  • Interferons
  • Others

By Age Group

  • Adults
  • Pediatric

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Hepatitis B, By Key Countries, 2025
  • 4.2. Key Industry Developments (Launches, Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Advancements in Hepatitis B Treatment
  • 4.5. Overview: Vaccination Coverage for Hepatitis B, Key Countries
  • 4.6. Impact of Tariffs on the Market

5. Global Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Nucleoside Analogues
    • 5.1.2. Nucleotide Analogues
    • 5.1.3. Interferons
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Age Group
    • 5.2.1. Adolts
    • 5.2.2. Pediatric
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Nucleoside Analogues
    • 6.1.2. Nucleotide Analogues
    • 6.1.3. Interferons
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Age Group
    • 6.2.1. Adolts
    • 6.2.2. Pediatric
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Nucleoside Analogues
    • 7.1.2. Nucleotide Analogues
    • 7.1.3. Interferons
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Age Group
    • 7.2.1. Adolts
    • 7.2.2. Pediatric
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Nucleoside Analogues
    • 8.1.2. Nucleotide Analogues
    • 8.1.3. Interferons
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Age Group
    • 8.2.1. Adolts
    • 8.2.2. Pediatric
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Nucleoside Analogues
    • 9.1.2. Nucleotide Analogues
    • 9.1.3. Interferons
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Age Group
    • 9.2.1. Adolts
    • 9.2.2. Pediatric
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Nucleoside Analogues
    • 10.1.2. Nucleotide Analogues
    • 10.1.3. Interferons
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Age Group
    • 10.2.1. Adolts
    • 10.2.2. Pediatric
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Gilead Sciences, Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Bristol-Myers Squibb Company
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. GSK plc
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Excision BioTherapeutics, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Arbutus Biopharma
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Assembly Biosciences, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Aligos Therapeutics
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Barinthus Biotherapeutics
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 3: Global Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 7: North America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 8: North America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 12: Europe Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 13: Europe Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 17: Asia Pacific Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 18: Asia Pacific Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Asia Pacific Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 22: Latin America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 23: Latin America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 24: Latin America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 27: Middle East & Africa Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 28: Middle East & Africa Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 29: Middle East & Africa Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Figure 1: Global Hepatitis B Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 4: Global Hepatitis B Therapeutics Market Value Share (%), by Route of Administration 2025 & 2034
  • Figure 5: Global Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Hepatitis B Therapeutics Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Hepatitis B Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 8: North America Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 9: North America Hepatitis B Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 10: North America Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 11: North America Hepatitis B Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 12: North America Hepatitis B Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Hepatitis B Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Hepatitis B Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Hepatitis B Therapeutics Market Value Share (%), By Country, 2025
  • Figure 17: Europe Hepatitis B Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 18: Europe Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 19: Europe Hepatitis B Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 20: Europe Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 21: Europe Hepatitis B Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 22: Europe Hepatitis B Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Hepatitis B Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Hepatitis B Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Hepatitis B Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Hepatitis B Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 28: Asia Pacific Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 29: Asia Pacific Hepatitis B Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 30: Asia Pacific Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 31: Asia Pacific Hepatitis B Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Hepatitis B Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Hepatitis B Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Hepatitis B Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Hepatitis B Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Hepatitis B Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Latin America Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 39: Latin America Hepatitis B Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 40: Latin America Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 41: Latin America Hepatitis B Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 42: Latin America Hepatitis B Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Latin America Hepatitis B Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Hepatitis B Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Hepatitis B Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Hepatitis B Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 48: Middle East & Africa Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 49: Middle East & Africa Hepatitis B Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 50: Middle East & Africa Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 51: Middle East & Africa Hepatitis B Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Hepatitis B Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Hepatitis B Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Hepatitis B Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Hepatitis B Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Hepatitis B Therapeutics Market Share (%), By Company, 2025